Goodwin Procter LLP advised C4 Therapeutics on the deal. C4 Therapeutics, Inc. (Nasdaq: CCCC) announced its upsized initial public offering for gross proceeds of $209.76 million,…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
